Lancet . 2011; RADIANT-2; Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2) a randomised, placeb

داروسازی دکتر عبیدی / مقالات / Lancet . 2011; RADIANT-2; Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2) a randomised, placeb